Publications by authors named "G Brent Young"
Background: Stroke secondary to intracranial atherosclerotic disease (ICAD) is associated with high recurrence risk despite currently available secondary prevention strategies. In patients with systemic atherosclerosis, a significant reduction of stroke risk with no increase in intracranial or fatal hemorrhage was seen when rivaroxaban 2.5 mg twice daily was added to aspirin.
View Article and Find Full Text PDFArticle Synopsis
- Large-scale studies are essential to investigate the gut microbiota's complex relationships with health and disease, and tissue preservation methods need evaluation for feasibility in such research.
- Biopsies from 20 adults with inflammatory bowel disease were preserved using three methods: flash freezing, nucleic acid preservative reagents, and formalin fixation with paraffin embedding (FFPE), with microbiota analyzed using sequencing.
- Results showed that while preservative reagents can serve as viable alternatives to flash freezing, FFPE samples exhibited distinct community structures, highlighting the potential utility of historical samples despite differences in microbial profiles.
Objectives: Virtual surgical planning (VSP) allows for optimal reconstruction of maxillary defects with fibula free flaps. Current data are limited regarding long-term complications of patient-specific plates (PSPs) in this setting. Our objective was to determine long-term complications of PSPs in maxillary reconstruction using fibula free flaps.
View Article and Find Full Text PDFPhages EarickHC, Figueroism, FinalFrontier, SBlackberry, Skylord, and Slay were isolated from soil samples collected around Southern California using the host All six phages are lytic and have a siphoviral morphology. Genomes are 39,843 to 52,992 bp in length and contain 58 to 91 protein coding genes.
View Article and Find Full Text PDFIntroduction: Eptacog beta is a novel human recombinant FVIIa approved for use in the United States, European Union, United Kingdom and Mexico for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors (≥12 years). It is also indicated for perioperative care in the same patient population in Europe and the United Kingdom.
Aim: To assess the incidence of rebleeding and review treatment outcomes in subjects with haemophilia with inhibitors enrolled in the phase 3 PERSEPT 1 clinical trial.